Standex International Corp/De/ (SXI) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Industrials / Manufacturing / Defense · as of Aug 11, 2026
Standex International Corp/De/ (SXI)
A forensic read on Standex International Corp/De/ built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
9.0
Distress distance
Clean
Earnings quality
6
Forensic signals
41.5
P / E (ttm)
7.8%
ROE
$4.0B
Market cap
0.40%
Dividend yield
9.6%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Standex International Corp/De/ earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 9.0, placing it in the Safe zone. 6 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
+61.2%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +61.2% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The build is led by inventory up +49% against +8% in cost of sales and receivables up +42% against revenue +10%. The cash-flow cross-check is more mixed: reported earnings ran in line with operating cash by 2% of net operating assets, diverging from the balance-sheet accrual read.
6.1%
FY2025
Return on invested capital.Return on invested capital is 6.1% in the latest fiscal year and slipping from 10% — well below its ~9% cost of capital, so reinvested dollars may be destroying value, not building it.
0.94×
FY2023–FY2025
Cash conversion.Over FY2023–FY2025, operating cash flow was 0.94× cumulative net income. Cash is lagging reported profit. The shortfall is profit tied up in working capital rather than collected — the accrual and receivables lines below show where.
83d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 77 to 83 FY2024→FY2025 (against cost of goods sold; inventory +49% vs +8% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.
-0.3%/yr
FY2022–FY2025
Key fundamentals
Latest Revenue$790.1M
Revenue Growth YoY+9.6%
Revenue CAGR (3yr)+2.4%
Net Margin7.1%
Free Cash Flow$41.3M
Return on Equity7.8%
Debt / Equity0.78x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Standex International Corp/De/'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.
Share count.Diluted share count changed -1% over the last 3 years to FY2025 (-0.3%/yr). Roughly flat — the count is neither shrinking nor growing meaningfully. Per-share value isn't being meaningfully helped or hurt by the count.
$8M
FY2021–FY2021
Goodwill impairments.Took $8M of goodwill writedowns across 1 year (FY2021 ($8M)) — about 21% of net income over the span. Writedowns mean past acquisitions underperformed what was paid for them.